Helix Biopharma Corp. Announces Voting Results from its Annual and Special Meeting of Shareholders

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on January 17, 2017 (the “Meeting”).